Evolus Announces First Shipment of Jeuveau™ (prabotulinumtoxinA-xvfs) to Customers in the United States

World News: . []

NEWPORT BEACH, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that with the U.S. launch of Jeuveau™ (prabotulinumtoxinA-xvfs), there’s a #NEWTOX on the market. Jeuveau™ was approved by U.S. Food and Drug Administration (FDA) in February 2019 for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyes) in adults and is the first neurotoxin in the U.S. developed with a specific focus in aesthetics.

Evolus is planning to launch the Jeuveau™ Experience Treatment (J.E.T.) through approximately 3,000 accounts nationwide. This limited-time-program is available through the company’s technology platform, Evolus Practice, which allows providers to open a new account, order product, track shipments, pay their invoices and engage with the customer experience team and medical affairs all through the company’s digital platform.

Jeuveau™ is now available throughout the United States. Providers and consumers are encouraged to visit  or  to find product and prescribing information and a medication guide.

The most common side effects include: headache; eyelid drooping, upper respiratory tract infection, and increased white blood cell count in your blood.

The risk information provided here is not complete. For more information about , the full Prescribing Information including BOXED WARNING, and Medication Guide, visit  or talk to your healthcare provider. 

Manufactured by: Evolus, Inc., 1027 Garden St., Santa Barbara, CA 93101

©2019 Evolus, Inc. All rights reserved. Jeuveau is a trademark of Evolus, Inc. All other trademarks are the property of their respective owners.

Jeuveau™ is a trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Botox®, Botox® Cosmetic, Myobloc®, Dysport®, and Xeomin® are registered trademarks of their respective owners.

* Responder rate = GLS = 0 or 1 at Maximum Frown Investigator Assessment

Media Contacts: Crystal Muilenburg, Evolus, Inc. Vice President, Corporate Communications & Public Relations Tel: +1-949-284-4506 Email: 

Investor Contacts: Ashwin Agarwal, Evolus, Inc. Vice President, Finance, Investor Relations & Treasury Tel: +1-949-284-4559 Email: 

More news and information about Evolus

Published By:

Globe Newswire: 14:00 GMT Wednesday 15th May 2019

Published: .

Search for other references to "evolus" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us